Phase II, Randomized Trial of Bevacizumab With or Without Sunitinib in Sunitinib-Refractory Patients With Metastatic Renal Cell Carcinoma.
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 30 Mar 2016
At a glance
- Drugs Bevacizumab (Primary) ; Sunitinib
- Indications Renal cancer
- Focus Biomarker; Therapeutic Use
- 19 Jul 2011 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 25 Sep 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 25 Sep 2009 Planned end date changed from 1 Dec 2010 to 1 Dec 2011 as reported by ClinicalTrials.gov.